NEW YORK, NY / ACCESSWIRE / August 20, 2020 / Conversion Labs, Inc. (OTCQB:CVLB), a direct-to-consumer telemedicine and wellness company, has been invited to present at LD Micro 500 virtual institutional investor conference being held on September 1-4, 2020.
CEO of Conversion Labs, Justin Schreiber, is scheduled to present on Tuesday, September 1, at 9:40 a.m. Eastern time. He will be joined by the company's CFO, Juan M. Piñeiro Dagnery, for the presentation and virtual one-on-one meetings with institutional analysts and investors.
The presentation will be webcast live and available for replay here and via the investor relations section of the company's website at www.conversionlabs.com.
Management will discuss the company's record results for the second quarter. Revenue was up 237% to $9.1 million, driven by increasing subscription-based revenue generated by Conversion Labs' new telehealth brands, including Rex MD, Shapiro MD and SOS Rx. Based on these results, the company increased its full-year 2020 revenue outlook from $36 million to more than $40 million.
Management will also discuss the launch of the company's new cloud-based telemedicine platform, Veritas MD. The state-of-the-art digital health platform has been designed to support the continued rapid scale up and market expansion of the company's telehealth brands, while providing easier, more convenient and affordable access to doctors for patients seeking treatment.
The LD 500 is one of the nation's largest independent conferences for micro-cap companies, with over 300 names presenting. The conference will also feature variety of speakers and panelists discussing topics of interest to investors and issuers.
To schedule a virtual one-on-one meeting with Conversion Labs, you may submit your request to register for the conference here or contact David Scher at [email protected] or visit www.ldmicro.com/events.
View Conversion Labs' LD Micro profile here: https://www.ldmicro.com/profile/CVLB
Profiles powered by LD Micro - News Compliments of Accesswire
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, LD 500, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For more information about LD Micro, go to www.ldmicro.com/events.
About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company's brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.
The company's PDFSimpli subsidiary is a software-as-a-service that allows users to convert, edit, sign, and share PDF documents online. For more information, go to PDFSimpli.com.
Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.
Trademarks are the property of their respective owners.
Company Contact
Conversion Labs
Juan Manuel Piñeiro Dagnery
CFO
Email Contact
Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact
SOURCE: Conversion Labs, Inc.